Trial tests best path forward for HIV patients with drug resistance

NCT ID NCT06747507

Recruiting now Disease control Sponsor: University of Nairobi Source: ClinicalTrials.gov ↗

Summary

This study aims to find the best treatment strategy for people with HIV whose current dolutegravir (DTG) medication is no longer fully effective due to drug resistance. Researchers will randomly assign 392 participants, including some children, to either continue their DTG-based treatment or switch to a different combination (darunavir/ritonavir). The main goal is to see which approach better controls the virus after 6 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bomu Hospital
NOT_YET_RECRUITING

Mombasa, Kenya

Contact
Butha-Buthe District Hospital
NOT_YET_RECRUITING

Butha-Buthe, Lesotho

Contact
CS Machava II
NOT_YET_RECRUITING

Maputo, Mozambique

Contact
CS Ndlavela
NOT_YET_RECRUITING

Maputo, Mozambique

Contact
CS Ponta Gea
NOT_YET_RECRUITING

Beira, Sofala, Mozambique

Contact
Jaramogi Oginga Odinga Teaching and Referral Hospital
RECRUITING

Kisumu, Kenya

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kenyatta National Hospital
RECRUITING

Nairobi, 00100, Kenya

Contact Phone: •••-•••-•••• Email: •••••@•••••
MUHAS Clinical Trial Unit
NOT_YET_RECRUITING

Dar es Salaam, Tanzania

Contact
Mokhotlong District Hospital
NOT_YET_RECRUITING

Mokhotlong, Lesotho

Contact

Conditions

Explore the condition pages connected to this study.

HIV-1-INFECTION